Fate Therapeutics/$FATE

1D1W1MYTD1Y5YMAX

About Fate Therapeutics

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Ticker
$FATE
Sector
Health
Primary listing
NASDAQ
Employees
161
Headquarters
San Diego, United States
Website
www.fatetherapeutics.com

FATE Metrics

BasicAdvanced
$303M
-
-$1.05
2.55
-

What the Analysts think about FATE

Analyst ratings (Buy, Hold, Sell) for Fate Therapeutics stock.
Analyst projections of the future price of Fate Therapeutics stock.

Bulls say / Bears say

Early FT819 data show meaningful clinical activity in difficult-to-treat lupus: month-six urine protein-to-creatinine ratios fell by 1.15 g/g across the reduced-conditioning group and by 1.8 g/g in the bendamustine subgroup. Patient-reported and disease-activity improvements were also maintained over time. (GlobeNewswire)
Fate has started RECLAIM-LN and treated its first patient in the Phase 2 potentially registrational trial, which was designed through discussions with the FDA under FT819’s RMAT designation. The first treatment was delivered as an outpatient with same-day discharge, supporting the company’s aim to make CAR T more accessible than conventional hospital-based treatment. (BioSpace, PharmaDeviceNews)
The pipeline is expanding beyond FT819: the FDA has cleared FT839’s IND for a Phase 1/2 autoimmune basket trial. Its dual CD19/CD38 design aims to target several disease-driving immune-cell types without conditioning chemotherapy, potentially widening Fate’s addressable market across autoimmune diseases. (BioSpace, GlobeNewswire)
The pivotal evidence is still narrow: RECLAIM-LN is a small, open-label, single-arm study, with enrolment expected to finish only in the first half of 2028. That leaves FT819’s durability, safety and ability to satisfy regulators unproven for several years. (PharmaDeviceNews)
Fate had $153.8 million of cash, equivalents and investments at the end of June, against a $30.2 million second-quarter net loss and $54.3 million of operating cash burn in the first half. The forecast runway into 2028 may not cover delays, longer follow-up or commercial preparation, leaving dilution or further financing as a risk. (Last10K, AInvest)
The autoimmune pivot faces competition from simpler approaches such as bispecific antibodies and T-cell engagers, as well as other cell-therapy developers. Even positive FT819 data may therefore not guarantee a durable market position or strong pricing power. (Seeking Alpha, Seeking Alpha)
Data summarised monthly by Lightyear AI. Last updated on 18 Sept 2026.

FATE Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

FATE Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing FATE

AllUSDEURGBP
Funds
Fund name
Fund size
$FATE weighting
iShares Healthcare Innovation$HEAL
$1.4B0.03%
iShares Ageing Population€AGED
€822M0.03%
iShares Healthcare Innovation€2B78
€1.2B0.03%
iShares Healthcare Innovation£DRDR
£1B0.03%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.